Clinical research has demonstrated the effectiveness of PD‐1/PD‐L1 inhibitors, such as pembrolizumab and nivolumab, in treating patients with brain metastases of NSCLC [208]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.